Scribe Therapeutics reported a net loss of $6.5 million ($2.62 per share) for the quarter ended June 30, 2026, compared to a $9.9 million loss in the prior year period. The company raised approximately $155.5 million in aggregate gross proceeds from its initial public offering and concurrent private placement with Sanofi, bringing total cash resources to roughly $183.6 million, which funds operations into the first half of 2029. Pipeline updates include initiating a Phase 1 trial for STX-1150, an epigenetic silencing therapy targeting LDL-C, and receiving over $25 million in CIRM grants to advance STX-1200 and STX-1400 toward clinical entry. Scribe Therapeutics is a clinical-stage biotechnology company engineering CRISPR-based technologies for cardiometabolic diseases.

Scribe Therapeutics Inc. filed its Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws, which became effective on July 27, 2026, in connection with the closing of its initial public offering. Scribe Therapeutics Inc. operates in the biotechnology industry and develops therapeutic solutions using gene editing technology.